Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5626) 5626
Publication (689) 689
Patent (260) 260
Newsletter (184) 184
Book Review (153) 153
Book Chapter (94) 94
Book / eBook (23) 23
Magazine Article (11) 11
Dissertation (10) 10
Conference Proceeding (9) 9
Newspaper Article (3) 3
Reference (2) 2
Transcript (2) 2
Data Set (1) 1
Government Document (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3339) 3339
index medicus (2084) 2084
nucleosides (1668) 1668
hiv (1553) 1553
hiv infections - drug therapy (1340) 1340
pharmacology & pharmacy (1232) 1232
infectious diseases (1120) 1120
antiviral agents (1073) 1073
male (1063) 1063
female (1039) 1039
hiv-1 - drug effects (959) 959
virology (935) 935
nucleoside analogs (884) 884
adult (861) 861
animals (834) 834
antiretroviral therapy (832) 832
biochemistry & molecular biology (803) 803
reverse transcriptase inhibitors - pharmacology (788) 788
anti-hiv agents - pharmacology (739) 739
mutation (694) 694
protease inhibitors (649) 649
reverse transcriptase inhibitors - therapeutic use (632) 632
human-immunodeficiency-virus (621) 621
drug resistance (619) 619
immunology (618) 618
middle aged (617) 617
anti-hiv agents - therapeutic use (616) 616
dna polymerases (609) 609
reverse-transcriptase inhibitors (596) 596
nucleoside reverse transcriptase inhibitors (592) 592
non-nucleoside reverse transcriptase inhibitors (578) 578
microbiology (575) 575
aids (548) 548
human immunodeficiency virus--hiv (538) 538
hiv infections - virology (535) 535
hiv-1 - genetics (525) 525
chemistry, medicinal (516) 516
drug therapy (511) 511
nucleotides (510) 510
research (500) 500
hiv-1 (496) 496
immunodeficiency-virus type-1 (496) 496
nucleoside (489) 489
analysis (485) 485
antiretroviral drugs (481) 481
therapy (476) 476
zidovudine (474) 474
rna-directed dna polymerase (469) 469
highly active antiretroviral therapy (458) 458
antiviral agents - pharmacology (457) 457
hiv infection (453) 453
lamivudine (436) 436
reverse-transcriptase (435) 435
health aspects (430) 430
virus diseases (428) 428
chemistry, organic (422) 422
chemistry (414) 414
inhibitors (405) 405
cell line (403) 403
in-vitro (392) 392
tenofovir (391) 391
hiv reverse transcriptase - antagonists & inhibitors (390) 390
infection (388) 388
drug therapy, combination (376) 376
reverse transcriptase inhibitors - chemistry (375) 375
nucleosides - pharmacology (358) 358
resistance (357) 357
organic chemistry (354) 354
reverse transcriptase (353) 353
structure-activity relationship (353) 353
reverse transcriptase inhibitors (350) 350
drug resistance, viral (349) 349
anti-hiv agents - adverse effects (346) 346
viruses (346) 346
dna (343) 343
hiv reverse transcriptase - genetics (341) 341
human immunodeficiency virus (341) 341
viral load (337) 337
replication (332) 332
hiv-1 - enzymology (330) 330
nucleosides - chemistry (328) 328
antiviral activity (325) 325
article (325) 325
toxicity (325) 325
nucleic acids (317) 317
treatment outcome (317) 317
reverse transcriptase inhibitors - adverse effects (313) 313
drugs (310) 310
anti-hiv agents - chemistry (309) 309
drug-resistance (304) 304
efavirenz (304) 304
derivatives (302) 302
analogs (295) 295
virus replication - drug effects (292) 292
models, molecular (285) 285
molecular structure (284) 284
rna (282) 282
adenine - analogs & derivatives (279) 279
sugars (277) 277
antiretroviral agents (275) 275
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Chemistry (A D Allen) - Stacks (3) 3
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
New College (Ivey) - Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6088) 6088
French (127) 127
German (40) 40
Spanish (29) 29
Chinese (19) 19
Russian (19) 19
Japanese (8) 8
Norwegian (5) 5
Czech (4) 4
Korean (4) 4
Turkish (4) 4
Portuguese (3) 3
Danish (2) 2
Finnish (2) 2
Icelandic (2) 2
Italian (2) 2
Polish (2) 2
Arabic (1) 1
Hungarian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity
by Fowler, Benjamin J and Gelfand, Bradley D and Kim, Younghee and Kerur, Nagaraj and Tarallo, Valeria and Hirano, Yoshio and Amarnath, Shoba and Fowler, Daniel H and Radwan, Marta and Young, Mark T and Pittman, Keir and Kubes, Paul and Agarwal, Hitesh K and Parang, Keykavous and Hinton, David R and Bastos-Carvalho, Ana and Li, Shengjian and Yasuma, Tetsuhiro and Mizutani, Takeshi and Yasuma, Reo and Wright, Charles and Ambati, Jayakrishna
Science, ISSN 0036-8075, 11/2014, Volume 346, Issue 6212, pp. 1000 - 1003
Nucleoside reverse transcriptase inhibitors (NRTIs) are mainstay therapeutics for HIV that block retrovirus replication. Alu (an endogenous retroelement that... 
P2X7 RECEPTOR | PATHOGENESIS | INTERLEUKIN-18 | P2X RECEPTOR | INFLAMMASOME ACTIVATION | MULTIDISCIPLINARY SCIENCES | MACULAR DEGENERATION | NLRP3 INFLAMMASOME | ATP RELEASE | VERSUS-HOST-DISEASE | CASPASE-1 ACTIVATION | Retinal Pigment Epithelium - metabolism | Apoptosis - drug effects | NLR Family, Pyrin Domain-Containing 3 Protein | Reverse Transcriptase Inhibitors - pharmacology | Caspase 1 - metabolism | Geographic Atrophy - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Hepatitis - drug therapy | Animals | Carrier Proteins - metabolism | Choroidal Neovascularization - drug therapy | Graft vs Host Disease - drug therapy | Inflammasomes - drug effects | Liver - drug effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Retinal Pigment Epithelium - physiology | Receptors, Purinergic P2X7 - metabolism | Mice | Reverse Transcriptase Inhibitors - therapeutic use | Alu Elements | Disease Models, Animal | Retinal Pigment Epithelium - drug effects | Prevention | Genetic research | Genetic aspects | Genetic transcription | Research | HIV (Viruses) | Virus research | Macular degeneration | Inhibitor drugs | Drug therapy | Ribonucleic acid--RNA | Human immunodeficiency virus--HIV | Atrophy | Drugs | Inhibitors | Ribonucleic acids | Blocking | Nucleosides | Activation | Grafting
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Novel HIV-1 reverse transcriptase inhibitors
by Jochmans, Dirk
Virus Research, ISSN 0168-1702, 2008, Volume 134, Issue 1, pp. 171 - 185
HIV-1 reverse transcriptase (RT) was the first viral enzyme to be targeted by anti-HIV drugs. Despite 20 years of experience with RT inhibitors, new ways to... 
HIV-1 | Investigational compounds | Mechanism of action | Reverse transcriptase inhibitor | RNASE-H | NONNUCLEOSIDE INHIBITORS | NUCLEOSIDE ANALOGS | EXPERIENCED HIV-1-INFECTED PATIENTS | mechanism of action | HUMAN-IMMUNODEFICIENCY-VIRUS | reverse transcriptase inhibitor | NUCLEOTIDE ANALOGS | IN-VITRO | VIROLOGY | ANTIVIRAL ACTIVITY | PLACEBO-CONTROLLED TRIAL | RIBONUCLEASE-H ACTIVITY | Reverse Transcriptase Inhibitors - isolation & purification | Amino Acid Sequence | HIV-1 - drug effects | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Models, Molecular | Reverse Transcriptase Inhibitors - pharmacology | Ribonuclease H - antagonists & inhibitors | Reverse Transcriptase Inhibitors - chemistry | HIV Reverse Transcriptase - metabolism | HIV Infections - drug therapy | HIV-1 - enzymology | Protein Conformation | Ribonuclease H - metabolism | DNA polymerases | Antiviral agents | Ribonuclease | HIV (Viruses) | Anti-HIV agents | Nucleoside analogs | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text HIV-1 reverse transcriptase inhibitors
by El Safadi, Yazan and Vivet-Boudou, Valérie and Marquet, Roland
Applied Microbiology and Biotechnology, ISSN 0175-7598, 6/2007, Volume 75, Issue 4, pp. 723 - 737
Reverse transcriptase (RT) is one of the three enzymes encoded by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of AIDS. Together with... 
Biotechnology | Chemistry | Microbiology | Microbial Genetics and Genomics | DEPENDENT PRIMER UNBLOCKING | NUCLEOSIDE ANALOGS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VITRO SELECTION | ZIDOVUDINE RESISTANCE MUTATIONS | THYMIDINE ANALOG MUTATIONS | PRE-STEADY-STATE | HUMAN-IMMUNODEFICIENCY-VIRUS | MITOCHONDRIAL-DNA POLYMERASE | BLOOD MONONUCLEAR-CELLS | DEFICIENCY SYNDROME AIDS | Nucleosides - therapeutic use | Reverse Transcriptase Inhibitors - toxicity | Nucleosides - chemistry | Phosphorylation | Anti-HIV Agents - toxicity | HIV-1 - drug effects | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Drug Resistance, Viral | Clinical Trials as Topic | Drug Approval | Reverse Transcriptase Inhibitors - chemistry | Anti-HIV Agents - chemistry | Drug Design | Nucleosides - toxicity | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Reverse Transcriptase Inhibitors - therapeutic use | Studies | Human immunodeficiency virus--HIV | Life Sciences | Biochemistry, Molecular Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Emerging reverse transcriptase inhibitors for HIV-1 infection
by Rai, Mohammad A and Pannek, Sam and Fichtenbaum, Carl J
Expert Opinion on Emerging Drugs, ISSN 1472-8214, 04/2018, Volume 23, Issue 2, pp. 149 - 157
Introduction: There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse... 
GS-9191 | Doravirine | nucleoside reverse transcriptase inhibitors | Elsulfavirine | HIV | non-nucleoside reverse transcriptase inhibitors | HIV reverse transcriptase inhibitors | NNRTI | MK-8591 | NRTI | CRYSTAL-STRUCTURES | ANTIRETROVIRAL THERAPY | DRUG-RESISTANCE | TENOFOVIR ALAFENAMIDE | NUCLEOSIDE | IN-VITRO | DISOPROXIL FUMARATE | IMMUNODEFICIENCY-VIRUS TYPE-1 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | CHRONIC KIDNEY-DISEASE | Anti-HIV Agents - pharmacology | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Drug Resistance, Viral | Reverse Transcriptase Inhibitors - pharmacology | Reverse Transcriptase Inhibitors - administration & dosage | Patient Satisfaction | Anti-HIV Agents - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Medication Adherence | Drug Interactions | HIV-1 - isolation & purification | Drug Design | HIV Infections - drug therapy | Non-nucleoside reverse transcriptase inhibitors | Nucleoside reverse transcriptase inhibitors | HIV Reverse Transcriptase Inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
by Cihlar, Tomas and Ray, Adrian S
Antiviral Research, ISSN 0166-3542, 2010, Volume 85, Issue 1, pp. 39 - 58
Twenty-five years ago, nucleoside analog 3′-azidothymidine (AZT) was shown to efficiently block the replication of HIV in cell culture. Subsequent studies... 
Nucleotide | NRTI resistance | Nucleoside | NRTI | HIV reverse transcriptase | HEPATITIS-B-VIRUS | HUMAN-IMMUNODEFICIENCY-VIRUS | ANTIRETROVIRAL-DRUG-RESISTANCE | TENOFOVIR DISOPROXIL FUMARATE | VIROLOGY | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | MITOCHONDRIAL-DNA POLYMERASE | INTRACELLULAR METABOLISM | IN-VITRO ACTIVITY | OXATHIOLANE-CYTOSINE NUCLEOSIDES | CLASS-SPARING REGIMENS | Anti-HIV Agents - pharmacology | Nucleosides - therapeutic use | Nucleotides - therapeutic use | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Nucleotides - pharmacology | Nucleosides - pharmacology | Zidovudine - pharmacology | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Zidovudine - therapeutic use | HIV - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
by Cohen, Calvin J, Dr and Andrade-Villanueva, Jaime, Prof and Clotet, Bonaventura, MD and Fourie, Jan, MD and Johnson, Margaret A, Prof and Ruxrungtham, Kiat, Prof and Wu, Hao, MD and Zorrilla, Carmen, MD and Crauwels, Herta, PhD and Rimsky, Laurence T, PhD and Vanveggel, Simon, MSc and Boven, Katia, MD and THRIVE Study Grp and THRIVE study group
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
by Bertoletti, Nicole and Chan, Albert H and Schinazi, Raymond F and Yin, Y. Whitney and Anderson, Karen S
Protein Science, ISSN 0961-8368, 09/2019, Volume 28, Issue 9, pp. 1664 - 1675
ABSTRACT The retrovirus HIV‐1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV‐1, of... 
emtricitabine | nucleoside reverse transcriptase inhibitors | macromolecular X‐ray crystallography | inhibitor–protein complexes | lamivudine | MITOCHONDRIAL TOXICITY | TRANSLOCATION | COMPLEX | DESIGN | MECHANISM | ANALOGS | ENANTIOMERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | macromolecular X-ray crystallography | FIDELITY | DNA | inhibitor-protein complexes | BINDING | Drugs | Emtricitabine | Antiretroviral drugs | RNA-directed DNA polymerase | DNA polymerase | Toxicity | Amino acids | Lamivudine | Mitochondrial DNA | DNA biosynthesis | Polymerase | Highly active antiretroviral therapy | Side effects | Inhibitors | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Nucleosides | Replication | Deoxyribonucleic acid--DNA | DNA-directed DNA polymerase | Crystal structure | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
by Margolis, David A, Dr and Brinson, Cynthia C, MD and Smith, Graham H R, MD and de Vente, Jerome, MD and Hagins, Debbie P, MD and Eron, Joseph J, Prof and Griffith, Sandy K, PharmD and Clair, Marty H St, BS and Stevens, Marita C, MD and Williams, Peter E, PhD and Ford, Susan L, PharmD and Stancil, Britt S, BS and Bomar, Melinda M, BS and Hudson, Krischan J, PhD and Smith, Kimberly Y, MD and Spreen, William R, PharmD and LA 116482 Study Team and LAI116482 Study Team
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 10, pp. 1145 - 1155
Summary Background In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone, and in... 
Infectious Disease | NON-INFERIORITY | DAILY ELVITEGRAVIR | INFECTIOUS DISEASES | TWICE-DAILY RALTEGRAVIR | INTEGRASE-INHIBITOR | GSK1265744 | SAFETY | TREATMENT-EXPERIENCED PATIENTS | EMTRICITABINE/TENOFOVIR DF | DOUBLE-BLIND | DOLUTEGRAVIR | Double-Blind Method | United States | HIV Infections - virology | Humans | Middle Aged | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Young Adult | Canada | Pyridones - administration & dosage | HIV-1 - isolation & purification | Anti-Retroviral Agents - administration & dosage | Adolescent | Adult | Female | HIV Infections - drug therapy | Aged | Antiretroviral Therapy, Highly Active - methods | Rilpivirine - administration & dosage | Highly active antiretroviral therapy | Antiviral agents | Nucleosides | Clinical trials | DNA polymerases | HIV (Viruses) | HIV infection | Adults | Analysis | Studies | Antiretroviral drugs | Hepatitis | Pain | Acquired immune deficiency syndrome--AIDS | Insomnia | Human immunodeficiency virus--HIV | Infections | Drug therapy | Drug dosages | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights